Erenumab, Fremanezumab Reduce Migraine Frequency, Burden
Both erenumab and fremanezumab are currently under review by the FDA for the treatment of migraine.
All articles by Alicia Ciccone
Clobazam Effective for Refractory Epilepsy in Children Younger Than 2
Clobazam is currently FDA-approved for the treatment of seizures associated with Lennox-Gastaut syndrome in children 2 years and older.
Foramen Ovale EEG Identifies Epileptogenic Zone in Mesial Temporal Lobe Epilepsy
The diagnostic tool may be especially useful in cases of nonlesional mesial temporal lobe epilepsy.
Alternative Therapies Improve Seizure Frequency, Quality of Life in Treatment-Refractory Epilepsy
Patients with refractory epilepsy who fail to benefit from 2 or more AEDs should be referred to alternative therapies.
Brainstem Damage in Epilepsy May Be Biomarker for Increased SUDEP Risk
Patients who died from suspected SUDEP had extensive damage to areas of the mid-brain and brainstem that control autonomic function.
Continuous Infusion in Refractory Status Epilepticus Linked to Increased Mortality, Longer Hospital Stay
Researchers compared outcomes between patients treated with continuous infusion or repeated doses of nonbenzodiazepine anti-seizure medication.
Cannabidiol Effective for Reducing Drop Seizures in Lennox-Gastaut Syndrome Regardless of Clobazam Use
The study was a post-hoc analysis of responders who were on or off concomitant clobazam.
Signficant Risk of Seizures After Stroke Treatment With Reperfusion Therapies
Patients undergoing treatment for ischemic stroke are at greater risk for seizure development.
Positive Airway Pressure Improves Seizure Control in Epilepsy and Obstructive Sleep Apnea
Treatment with positive airway pressure may help retain or improve seizure control in patients with epilepsy and obstructive sleep apnea.
Early Surgical Intervention Improves Likelihood of Good Cognitive Outcomes in Epilepsy
Preoperative cognitive function is a central component of predicting cognitive outcomes after resective epilepsy surgery.
- Loading...
Loading...
Next post in AES 2017
Loading... 
Loading...